Instructions for Authors

Scope

Clinical Cancer Research, a new journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

Editorial Policy

When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, and Associate Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. A copy of the Declaration is available from the American Medical Association, P.O. Box 7046, Dover, DE 19903-7046. For animal experimentation reported in the journal, it is expected that investigators will have observed the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education issued by the New York Academy of Sciences’ Ad Hoc Committee on Animal Research, a copy of which is available for $5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator’s Institutional Review Board.

Review Process

The review process, expedited by fax transmission and overnight mail service, is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

Manuscript Submission

Send manuscripts to John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research, at Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in Clinical Cancer Research that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

The letter of submission should suggest the Associate Editor (or Editor-in-Chief) who will serve as primary reviewer of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of up to five potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

Format

Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
8. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;

References
Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

SAMPLE REFERENCES:

Figures
Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author’s name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity.
Authors are encouraged to submit color figures. The expense of reproducing color photographs will be charged to the authors. Submit color figures on flexible backing.

Typesetting Manuscripts from Computer Disks
Clinical Cancer Research welcomes disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author’s responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

For more information, contact:
John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, Telephone 212-639-6317, Fax 212-717-3629
or:
AMERICAN ASSOCIATION FOR CANCER RESEARCH
GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP
The American Association for Cancer Research (AACR), a scientific society of over 10,000 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:
1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. an advance copy of the Program and Proceedings of the American Association for Cancer Research pertaining to each annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focused meetings in the AACR's exciting series of Special Conferences in Cancer Research;
5. reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announcements;
8. early notification of and reduced rates for participation in the AACR Employment Register;
9. an up-to-date Membership Directory of thousands of researchers in the cancer field;
10. the professional benefits of AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
11. participation in Summer Workshops that foster networking opportunities and science education for young investigators; and
12. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP
Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If the candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION
There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application in AACR Office</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:
1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. -OR- The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). -OR- The seconder may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215-440-9313

RESPONSIBILITIES OF MEMBERSHIP
Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1996 annual dues for active members are $160, $95 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year’s membership dues are paid in full.

Corresponding members are required to pay dues ($80 in 1996) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates. Applicants elected in March will be responsible for payment of that year’s dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director
# APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

**NAME OF CANDIDATE:**

<table>
<thead>
<tr>
<th>LAST</th>
<th>FIRST</th>
<th>M.I.</th>
<th>DATE OF BIRTH:</th>
</tr>
</thead>
</table>

**PRESENT POSITION/TITLE:**

**INSTITUTIONAL AFFILIATION:**

**INSTITUTIONAL ADDRESS:**

<table>
<thead>
<tr>
<th>(City)</th>
<th>(State/Province)</th>
<th>(Country)</th>
<th>(Postal Code)</th>
</tr>
</thead>
</table>

**TELEPHONE NUMBER:**

**E-MAIL NUMBER (CARRIER):**

**FAX NUMBER:**

**PRIMARY FIELD OF RESEARCH** (Please check only one):

- Biochemistry and Biophysics
- Biostatistics
- Carcinogenesis
- Cellular Biology and Genetics
- Clinical Investigations
- Endocrinology
- Epidemiology
- Immunology
- Molecular Biology and Genetics
- Preclinical Pharmacology and Experimental Therapeutics
- Virology
- Other: ___

**ACADEMIC DEGREES** (Including where and when granted)

**EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED** (Please list most recent first)

**PUBLICATIONS** (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

**CANDIDATE NOMINATED BY**: ___

(Please print)

**CANDIDATE SECONDED BY**: ___

(Please print)

**CANDIDATE IS APPLYING FOR** (Check one):

- [ ] ACTIVE
- [ ] CORRESPONDING
- [ ] MEMBERSHIP

**STATEMENT OF SUPPORT**

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

How long has the candidate worked in the field of cancer research? ___ years

Will the candidate make a long-term contribution to cancer research? ___Yes ___No

Does the candidate's research adhere to accepted ethical standards? ___Yes ___No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

Signature of nominator* ___ Date ___

Signature of seconder* ___ Date ___

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.

(This form may be reproduced.)
QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a paper for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work (In this instance, the member who co-signs the abstract does not lose his or her own sponsorship privilege);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the Proceedings of the American Association for Cancer Research which contains abstracts of all papers being presented at each annual meeting;
3. the privilege of registering for the annual meeting at the low student rate (This rate is otherwise available only to predoctoral students);
4. preferred access to the AACR Employment Register;
5. optional subscriptions to the Association’s high-quality journals Cancer Research, Cell Growth & Differentiation, Cancer Epidemiology, Biomarkers & Prevention, and Clinical Cancer Research at reduced member rates;
6. priority notification of events in the AACR’s series of special conferences on timely subjects in the field;
7. reduced registration rates at special conferences;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date membership directory; and
9. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year’s dues payment must accompany the application. Dues for 1994 are $30 for associate members residing in the Americas and $40 for residents of other countries. For 1995 these rates are $35 and $45, respectively. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
215/440-9300

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1994 have been set at $30 per year for residents of the Americas and $40 for residents of other countries. For 1995 these rates are $35 and $45, respectively. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in October 1994 for the forthcoming annual meeting must have paid dues for 1994. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Cell Growth & Differentiation, Cancer Epidemiology, Biomarkers & Prevention, and Clinical Cancer Research at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member’s current registrar, dean, or department head, verifying the member’s current academic status. The Association’s By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1994 may retain associate membership until December 31, 1998. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti
Executive Director
# APPLICATION FOR ASSOCIATE MEMBERSHIP

**NAME OF CANDIDATE:**

| LAST | FIRST | M.I. | DATE OF BIRTH: |

**INSTITUTIONAL AFFILIATION:**

**INSTITUTIONAL ADDRESS:**

| (City) | (State/Province) | (Country) | (Postal Code) |

**TELEPHONE NUMBER:**

**FAX NUMBER:**

**PRESENT ACADEMIC STATUS/TITLE (Please check only one):**

- [ ] Graduate Student
- [ ] Medical Student
- [ ] Physician in Training
- [ ] Postdoctoral Fellow

**E-MAIL NUMBER (CARRIER):**

**PRIMARY FIELD OF RESEARCH (Please check only one):**

- [ ] Biochemistry and Biophysics
- [ ] Biostatistics
- [ ] Cellular Biology and Genetics
- [ ] Clinical Investigations
- [ ] Carcinogenesis
- [ ] Endocrinology
- [ ] Epidemiology
- [ ] Immunology
- [ ] Molecular Biology and Genetics
- [ ] Preclinical Pharmacology and Experimental Therapeutics
- [ ] Other: __________________________

(Please specify)

**ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)**

| Degree | Institution | Date |

**RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)**

| Experience | Institution |

**PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)**

| Authors | Title | Journal | Volume | Pages | Year |

**CANDIDATE NOMINATED BY:**

(Please type or print name of AACR member* in good standing.)

**SIGNATURES**

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: __________________________ Date: __________

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: __________________________ Date: __________

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year's dues. For 1994 dues are $30 for associate members residing in the Americas and $40 for residents of other countries. For 1995, these rates will be $35 and $45, respectively.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

[ ] The enclosed dues payment should be applied to the □ current □ forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March or April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced.)
Guidelines for Submitting Disks to American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

- MacWrite
- Microsoft Word (DOS, Windows, and Macintosh)
- WordPerfect (DOS, Windows, and Macintosh)
- XyWrite (DOS and Windows)

Also acceptable:

- Ability
- AmiPro
- A{l}S-TeX
- Appleworks
- ArborTeX
- ArborText
- ClarisWorks WP
- CPT 8000
- CTOS
- Diablo
- DisplayWrite
- Duet
- Einstein
- Enable
- EXP
- Final Word
- FullWrite
- GemWord Plus
- IBM Writing Assistant
- Interleaf
- LaTeX
- Leading Edge
- Lotus Manuscript
- Lotus Write
- Mass 11
- MS Windows Write
- MS Works
- MS Works WP Mac
- Multimate
- Multimate Advantage
- Nibia
- OfficeWriter
- PC Write
- PFS First Choice
- Professional Write
- Q&A Write
- Quark XPress
- RagTime MS Works
- Rich Text Format
- RSG (to ASCII file)
- Signature
- SLITeX
- SmartWhere
- SmartWrite II
- SunWrite
- Symphony
- SoloWriter
- Stx
- Sprint
- Symphony
- TeX
- TeX78
- Text EXecutive
- Textures
- Total Word
- Troff
- μTeX
- Volkswriter
- VuWriter
- Wang OIS
- Wang WPS
- Wang Writer
- Window Works
- Windows Write
- WiziWord
- Wordstar
- Wordstar 2000
- WriteNow
- Xerox

Software packages that we are unable to translate:

- FrameMaker
- PageMaker
- Ready, Set, Go
- Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: __________________________________________
Name of computer used (e.g., IBM/PS2): ______________________________________
Operating system and version (e.g., DOS 3.3): _________________________________
Word processing program and version (e.g., WordPerfect 5.0): ____________________
   [See reverse for acceptable programs.]

Manuscript number: _________________________________________________________
First author: _______________________________________________________________
Corresponding author (if different from first author): ____________________________
Telephone/FAX numbers: ___________________________________________________
NOVEMBER 17-21, 1995
Novel Strategies Against Resistant Cancers
Chairpersons: Victor Ling, Vancouver, B.C., Canada; Daniel D. Von Hoff, San Antonio, TX
Sanibel Harbour Resort & Spa, Ft. Myers, FL

DECEMBER 2-6, 1995
The Molecular Basis of Gene Transcription
Chairperson: Tom Curran, Memphis, TN
Hotel Del Coronado, San Diego, CA

JANUARY 17-20, 1996
Cancer and the Cell Cycle
Joint Meeting with the Swiss Institute for Experimental Cancer Research
Chairpersons: Edward E. Harlow, Charlestown, MA; Viesturs Simanis, Lausanne, Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

FEBRUARY 19-25, 1996
Cancer Susceptibility Genes and Molecular Carcinogenesis
Chairpersons: Curtis C. Harris, Bethesda, MD; Allan Balmain, Glasgow, Scotland; Kenneth Olden, Research Triangle Park, NC
Keystone Resort, Keystone, CO

MARCH 1-5, 1996
Proteases and Protease Inhibitors in Cancer
Chairpersons: Lynn M. Matrisian, Nashville, TN; Bonnie F. Sloane, Detroit, MI
Marriott's Bay Point Resort, Panama City Beach, FL

APRIL 20-24, 1996
87th Annual Meeting
Chairperson: Lorraine J. Gudas, New York, NY
Washington D.C. Convention Center, Washington, D.C.
Abstract Deadline: December 1, 1995

JUNE 8-12, 1996
Inducible Genomic Responses
Chairpersons: William T. Beck, Memphis, TN; John A. Hickman, Birmingham, England; Richard I. Morimoto, Evanston, IL
Skamania Lodge, Stevenson (Columbia River Gorge), WA

OCTOBER 2-6, 1996
Novel Approaches in Blood and Marrow Transplantation
Second Annual Meeting of the American Society for Blood and Marrow Transplantation
Chairpersons: O. Michael Colvin, Baltimore, MD; Bruce R. Blazar, Minneapolis, MN
Hotel Del Coronado, San Diego, CA

OCTOBER 6-9, 1996
Carcinogenesis from Environmental Pollution: Assessment of Human Risks and Strategies for Prevention
Joint Meeting with International Agency for Research on Cancer
Chairpersons: Frederica Perera, New York, NY; Paul Kleihues, Lyon, France
Hotel Gellért, Budapest, Hungary

OCTOBER 19-23, 1996
Programmed Cell Death
Chairperson: Stanley J. Korsmeyer, St. Louis, MO
The Sagamore, Bolton Landing (Lake George), NY

NOVEMBER 16-20, 1996
Disrupted Transcription Factors in Cancer
Chairpersons: Peter K. Vogt, La Jolla, CA; Frank J. Rauscher III, Philadelphia, PA
Hotel Del Coronado, San Diego, CA

FEBRUARY 13-16, 1997
Growth Factors and Cancer
Joint Meeting with Lorne Cancer Congress
Chairpersons: Antony Burgess, Parkville, Victoria, Australia; Robert S. Coffey, Nashville, TN; Ashley R. Dunn, Parkville, Victoria, Australia; Raymond L. White, Salt Lake City, UT
Erskine House, Lorne, Victoria, Australia

AACR members will receive brochures on the above special conferences as soon as they are available. Nonmembers should call or write:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
E-Mail: aacr@aol.com
1996 ANNUAL MEETING
TITLES OF MAJOR SESSIONS
(Confirmed Chairpersons in Parentheses)

AMERICAN ASSOCIATION FOR CANCER RESEARCH

Special Plenary Session
Twenty-fifth Anniversary of the National Cancer Act: Progress and Promise (Joseph R. Bertino)

Symposia
Apoptosis: Manipulating Programmed Cell Death in Cancer (David E. Fisher)
Matrix Metalloproteases and Inhibitors (Lynn M. Matrisian)
Cell Cycle: Targets for Therapy (Stephen H. Friend)
Endogenous DNA Damage: Detection and Biological Significance (John M. Eissigmann)
Cell Signalling
Recent Developments in Gene Therapy (Drew M. Pardoll)
Cancer Chemoprevention in Humans (Thomas W. Kensler)
Genetic Predisposition to Cancer (Mark H. Skolnick)
Cell Responses to DNA Damaging Agents (Nathan A. Berger)
Drug Resistance: Transcriptional and Translational Mechanisms (Kathleen W. Scotto)
Monoclonal Antibodies: Clinical Mechanisms and Effectiveness
Targeting Growth Factor Receptors for Therapy (John Mendelsohn)
Melanoma as a Clinical Model (Alan N. Houghton)
Thymidylate Synthetase and Its Inhibitors
Nutrition and Cancer (Walter C. Willett)
Aberrant Transcription Factors and Malignancy (Lorraine J. Gudas)
Steroid Hormones: Breast and Prostate Cancer (Myles A. Brown)
Viral Mechanisms of Carcinogenesis (Harald zur Hausen)
Tumor Suppressor Genes (Bert Vogelstein)
Ovarian Cancer: From the Laboratory to the Clinic (Robert F. Ozols)
Drug Metabolizing Enzymes in Cancer Prevention and Therapy (Cecil B. Pickett)
Cell Adhesion Molecules and the Cytoskeleton (Jun-Lin Guan and Rudolph L. Juliano)
Tumor Angiogenesis (Judah Folkman and Mark A. Goldberg)
Gynecoblastoma: Recent Advances in Diagnosis and Treatment (Garrett M. Brodeur)
Telomerases, Cell Senescence, and Cancer (Calvin B. Harley)

Pre-Meeting Methods Workshops
Quantitative Biology and Pharmacodynamics (Robert C. Jackson)
Animal Models: Transgenic and Knockout Mice in Cancer Investigations

Controversy Sessions
Does Regional Chemotherapy Work? (David S. Alberts)
Is Beta-Carotene Useful in Cancer Prevention? (Waun Ki Hong)
In Studies of Drug Resistance, Have Preclinical Models Provided Accurate Predictions for Clinicians? (Bruce A. Chabner)
Is p53/Rb Important for Therapeutic Outcome? (William F. Benedict)
Should Genetic Testing Be Done on Patients to Assess Cancer Risk? (Judy E. Garber)

Meet-The-Expert Sunrise Sessions
Quantitative PCR As a Tool to Detect Minimal Residual Disease in Lymphoma and Leukemia (John Gribben)
Inhibition of Tobacco-induced Carcinogenesis (Stephen S. Hecht)
Cell Cycle (Peggy J. Farnham)
Drugs Which Interact with Microtubules: An Update (Eric K. Rowinsky)
Culturing Normal and Neoplastically Transformed Human Epithelial Cells (Martha R. Stampfer)
Mammary Carcinogenesis (Daniel Medina)
Radiation Sensitization (Theodore S. Lawrence)
NMR As a Prognosticator (Jerry D. Glickson)
Antiestrogens (V. Craig Jordan)
DNA Topoisomerases and Their Inhibitors (Yves G. Pommier)
Estrogens and Breast Cancer (Lovell A. Jones)
Tumor Physiology (Rakesh K. Jain)
Protein Kinase C in Cell Transformation (Susan Jaken)
Environmental Carcinogens: Their Impact in Cancer (John A. McLachlan)
Lung Cancer: A Primer
Chromosomal Deletions and Cancer: Recent Advances in Mapping Techniques (Funmi I. Olopade)
Tumor Vaccines (Jeffrey Schom)
Challenges in Bone Marrow Transplantation (William S. Dalton)
Immunologic Features of AIDS Pathogenesis (Jay A. Levy)
Natural Killer Cells (Ronald B. Herberman)
Interferons and Cancer (Ernest C. Borden)
Transcription Factors As Therapeutic Targets (Richard A. Heyman)
Chemokines and Leukocyte-specific Chemotactic and Activating Factors (Barrett J. Rollins)
Bcl and Cell Death (Stanley J. Korsmeyer)
Prodrugs (Peter D. Senter)
Reconstruction of Complex Tissues in Culture and Tumorigenesis (Drane F. Birt)
Childhood Leukemias: The Latest in Treatment (Steven E. Sallan)

April 20-24, 1996
Washington, D.C.
Convention Center

The Latest Developments in All Areas of Cancer Research

Program Chairperson:
Lorraine J. Gudas

Major Presentations by the Foremost Scientists in the Field

Minisymposia, Poster Discussion Sessions, and Poster Sessions of Proffered Papers

Abstract Deadline: December 1, 1995

For More Information:
AACR Office
Public Ledger Building
Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300
Fax 215-440-9313
Email aacr@aol.com

An Essential Multidisciplinary Program for Laboratory and Clinical Cancer Researchers